Miyashita Yudai, Kanou Takashi, Isono Tomomi, Ishida Hiroto, Nagata Hideki, Sakurai Teiko, Kimura Kenji, Fukui Eriko, Kimura Toru, Ose Naoko, Watabe Tadashi, Shintani Yasushi
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, 2-15 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Surg Today. 2025 Apr;55(4):569-578. doi: 10.1007/s00595-024-02954-3. Epub 2024 Dec 5.
To investigate the role of F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.
The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.
Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).
Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.
探讨氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)在评估胸腺癌患者诱导治疗后的病理反应和预后中的作用。
本回顾性研究的对象为18例接受诱导治疗前后FDG-PET检查的胸腺癌患者。我们测量了肿瘤的最大标准化摄取值(SUVmax),并分析了SUVmax变化与病理反应或复发之间的相关性。
大多数患者诱导治疗后肿瘤大小和SUVmax均降低。肿瘤大小变化与SUVmax变化之间存在强相关性(Pearson系数=0.90,p<0.0001)。虽然SUVmax和肿瘤大小与病理反应无关,但SUVmax变化>50%预示着较低的复发率(p=0.03)。
诱导治疗后SUVmax的变化可能是胸腺癌患者复发的有价值预测指标。这一发现凸显了FDG-PET作为监测该罕见癌种患者和进行预后评估工具的潜力。有必要进一步开展研究以验证这些结果,并规范FDG-PET方案以实现最佳临床应用。